Climbazole Ups Retinoid-Linked Biological Activities

Share this content:
Climbazole Ups Retinoid-Linked Biological Activities
Climbazole Ups Retinoid-Linked Biological Activities

WEDNESDAY, Jan. 25, 2017 (HealthDay News) -- Climbazole enhances retinoid-associated biological activities in vivo and in vitro, according to a study published online Jan. 19 in the International Journal of Cosmetic Science.

Jean Adamus and colleagues from Unilever R & D in Trumbull, Conn., assessed cellular retinoic acid-binding protein 2 (CRABP2) mRNA expression by real time-qualitative polymerase chain reaction after treating primary human dermal fibroblasts (HDFs) from six to 48 hours with retinoids alone or in combination with climbazole. Skin equivalent (SE) cultures were topically treated with a retinol or retinyl propionate, with or without climbazole. On the outer forearm of 16 subjects, the authors ascertained the effects of low or high levels of retinol, retinyl propionate, climbazole, or a combination or retinol/climbazole.

The researchers found that treatment of HDFs with retinol or retinyl propionate resulted in significantly higher sustained CRABP2 mRNA expression compared with treatment with retinyl palmitate or vehicle control, but the treatments were unaffected by climbazole. Climbazole combined with retinol or retinyl propionate boosted retinoid-related activity more than the retinoid alone in SEs. Low-dose retinol or climbazole alone did not increase most evaluated biomarkers, but in combination there were significant increases in retinoid and aging biomarkers.

"Based upon the evidence presented here, we suggest that the topical skin application of climbazole in combination with retinoids, could deliver skin aging benefits more than a less robust retinoid alone," the authors write.

All the authors and employees of Unilever R & D, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »